Project Grant R01CA300284
Award Date
4/1/25
Completion Date
3/31/30
Dollars Obligated
$563K
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
Charleston, SC 29425, USA
Similar Awards
This $649,679 Project Grant from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) will fund research conducted by The Institute For Cancer Research to investigate a novel strategy for enhancing cancer immunotherapy responsiveness. The project aims to determine if targeting the RNA/DNA helicase DHX9 can induce "viral mimicry" in small cell lung cancer cells, triggering an antiviral immune response and improving the efficacy of immune checkpoint blockade...
The National Cancer Institute (NCI) awarded a $674,996 Project Grant under the Cancer Biology Research program (CFDA 93.396) to the Sanford Burnham Prebys Medical Discovery Institute. The goal of this 5-year project is to determine whether targeting the PSGL-1 immune checkpoint can promote the development and persistence of T cells essential for anti-tumor responses to PD-1 immune checkpoint blockade therapy. The research aims to elucidate the role of PSGL-1 in driving T cell exhaustion and...
The National Cancer Institute (NCI), part of the National Institutes of Health (NIH), awarded a $695,916 Project Grant (CFDA 93.395 - Cancer Treatment Research) to The Regents of the University of California, San Francisco (UCSF) to evaluate and optimize novel nSMase2 inhibitors for enhancing immune checkpoint inhibitor (ICI) response in cancer treatment.
The grant aims to synthesize and test analogs of the nSMase2 inhibitor PDDC to improve its potency, solubility, and pharmacokinetics....
The National Cancer Institute (NCI) awarded a 5-year, $709,554 Project Grant (CFDA 93.395 - Cancer Treatment Research) to Emory University to advance the understanding of how a novel neoadjuvant therapy impacts the immune system in patients with solid tumors, using refractory melanoma as a model. The key objectives are to:
Gain insights on how blocking the Semaphorin 4D (SEMA4D) protein, when combined with immune checkpoint blockade, affects the induction and infiltration of...
This $351,131 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) will support research at the University of Miami to disrupt the interactions between myeloid-derived suppressor cells (MDSCs) and cancer-associated fibroblasts (CAFs) in order to overcome resistance to chemoimmunotherapy in pancreatic cancer. The key objectives are to: 1) Mechanistically dissect the signaling and spatial interactions between MDSC-derived transmembrane TNF and...
This $450,429 Project Grant award from the National Cancer Institute (NCI), part of the National Institutes of Health, supports research to advance immunotherapy for non-small cell lung cancer (NSCLC) by targeting the MUC1-C protein. The goal is to identify novel therapeutic strategies using anti-MUC1-C antibody-drug conjugates (ADCs) alone and in combination with immune checkpoint inhibitors (ICIs) to enhance anti-tumor immunity and restrain NSCLC progression, particularly for EGFR-mutant...
This $626,534 federal Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) supports research by the Medical University of South Carolina (MUSC) to investigate how targeting endoplasmic reticulum (ER) stress and autophagy in T cells can reinvigorate anti-tumor immunity. The research aims to:
Determine how ER stress-induced mitochondrial quality control mechanisms regulate T cell effector function.
Assess how autophagy-induced metabolic changes...
This Project Grant award from the National Cancer Institute (NCI), under the 21st Century Cures Act - Beau Biden Cancer Moonshot program (CFDA 93.353), provides $524,709 to the University of South Carolina to investigate the role of transforming growth factor 2 (TGFB2) and macrophages in cancer cachexia. The research aims to uncover the involvement of TGFB2 in initiating fibrosis and activating M2 macrophages in the skeletal muscle of cancer cachexia mouse models. Additionally, the study will...
This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $196,029 to the University of Massachusetts Medical School (UMass Medical) to support research aimed at deciphering the immune evasion mechanisms in cancers harboring mutations in the isocitrate dehydrogenase 1 (mIDH1) gene. The funded work will focus on two key objectives: 1) Elucidating the role of viral mimicry in the response to mIDH1 inhibition, and 2) Exploring the contribution...
The National Cancer Institute (NCI) awarded a $176,040 Project Grant under the Cancer Research Manpower program (CFDA 93.398) to The General Hospital Corporation's Research Management Division, doing business as Massachusetts General Hospital (MGH). The grant will fund research to investigate the effect of aging on conventional type 1 dendritic cells (CDC1s) and their impact on CD8+ T cell immunity in tumor models.
The research aims to elucidate the mechanisms by which aged intratumoral CDC1s...